Skip to main content

Table 4 Secondary outcome measures (PO = Prescribing outcomes)

From: A cluster randomised stepped wedge trial to evaluate the effectiveness of a multifaceted information technology-based intervention in reducing high-risk prescribing of non-steroidal anti-inflammatory drugs and antiplatelets in primary medical care: The DQIP study protocol

Number Risk factor (Denominator)

High-risk prescription definition (Numerator)

PO-1

Number of patients with a Read Code for peptic ulceration ever recorded

Number of denominator patients prescribed a traditional oral NSAID¶ or low dose aspirin in the previous eight weeks who have NOT been prescribed a gastro-protective drug in the 12 weeks before, or since the most recent NSAID or aspirin prescription

PO-2

Number of patients aged 75 and over

Number of denominator patients prescribed a traditional oral NSAID¶ in the previous eight weeks who have NOT been prescribed a gastro-protective drug in the 12 weeks before, or since the most recent NSAID prescription

PO-3

Number of patients aged 65 and over prescribed aspirin in the previous 12 weeks

Number of denominator patients prescribed a traditional oral NSAID¶ in the previous eight weeks who have NOT been prescribed a gastro-protective drug in the 12 weeks before, or since the most recent NSAID or aspirin prescription

PO-4

Number of patients aged 65 and over prescribed aspirin in the previous 12 weeks

Number of denominator patients prescribed clopidogrel in the previous eight weeks who have NOT been prescribed a gastro-protective drug in the 12 weeks before, or since the most recent aspirin or clopidgrel prescription

PO-5

Number of patients prescribed warfarin in the previous 12 weeks

Number of denominator patients prescribed a traditional oral NSAID¶ in the previous eight weeks who have NOT been prescribed a gastro-protective drug in the 12 weeks before, or since the NSAID prescription

PO-6

Number of patients prescribed warfarin in the previous 12 weeks

Number of denominator patients prescribed low dose aspirin or clopidogrel in the previous eight weeks who have NOT been prescribed a gastro-protective drug in the 12 weeks before, or since the aspirin or clopidogrel prescription

PO-7

Number of patients with a QOF heart failure code ever recorded

Number of denominator patients prescribed any oral NSAID in the previous eight weeks

PO-8

Number of patients prescribed both a diuretic and an ACE inhibitor/ARB in the previous 12 weeks

Number of denominator patients prescribed any oral NSAID in the previous eight weeks

PO-9

Number of patients with a QOF CKD (stage 3, 4, or 5) code recorded as the most recent CKD code

Number of denominator patients prescribed any oral NSAID in the previous eight weeks

PO-10

GI risk composite

Number of patients with any risk factors as defined in PO-measures 1 to 6

Number of denominator patients with any high-risk prescription as defined in PO-measures 1 to 6

PO-11

Renal risk composite

Number of patients with any risk factors in PO-measures 8 to 9

Number of denominator patients with any high-risk prescription as defined in PO-measures 8 to 9

  1. ¶ 'Traditional' NSAID means all representatives of this class except Cox-2 selective agents, such as celecoxib;
  2. Key: NSAID = Non-steroidal anti-inflammatory drug; QOF = Quality and outcomes framework; CKD = chronic kidney disease; ACE = angiotensin converting enzyme; ARB = Angiotensin Receptor Blocker